Fulgent Genetics heads into its third-quarter report with an unusual problem. Demand looks fine, but the company has been struggling to get paid for the work it does. Last quarter, management blamed a self-inflicted transition to a new revenue-cycle and billing system for lower collection rates. It then cut nearly every piece of its 2026 outlook. The results due after the close on November 5 will show whether that damage is stabilizing or still spreading.
The Street expects a loss of $1.00 per share on revenue of $86.3 million. Revenue would be up a modest 2.7% from a year ago and barely above the second quarter's $85.4 million. The earnings picture is far worse. The year-ago loss was just $0.16 a share, and the expected loss is also deeper than last quarter's $0.88. That points to analysts assuming margins stay under pressure while collections remain impaired. Management now guides 2026 revenue to $330 million to $340 million and a loss of $2.22 to $2.35 per share. Consensus sits at $352.2 million in revenue and a $2.81 loss for the year, which is an odd combination. On the top line, the Street is above the company's range. On the bottom line, it is meaningfully more pessimistic than management. Either analysts doubt the cost side of the plan, or their revenue models have not fully caught up with the cut. Both gaps give this report room to reset expectations.
The billing system is the swing factor. Management argued that without the revenue-cycle problem, the second quarter would have matched plan and guidance would have held. The issue is that the final phase of the system lacked key customizations needed to maximize reimbursement, and no firm recovery timeline was given. A credible update would validate the narrative: evidence that those customizations are in place, collection rates are improving, and the mid-30% non-GAAP gross margin target for the year is still achievable. Another quarter of slippage, or vague language about timing, would suggest the problem runs deeper than a temporary transition.
The operating story outside billing deserves attention too. Anatomic pathology jumped to $37.5 million last quarter on a full period of the Bako and Strata acquisitions. Yet that segment's full-year guide was trimmed to $146 million to $150 million, so sustaining a similar run rate matters. Precision diagnostics faces a known headwind as the largest customer keeps bringing testing in-house, and management warned of further declines in the back half. Biopharma services, guided up to $23 million to $24 million, is a smaller but encouraging offset. Watch for progress on the Epic Aura go-live with early adopters, which was slated for the third quarter, and on the year-end cash forecast of about $610 million, which has already fallen twice this year.
The therapeutic pipeline adds an option-like layer. FID-07 had an end-of-Phase 2 meeting with the FDA planned for the summer, with a Phase 3 registration trial targeted for the first half of 2027. Any readout from that meeting could color sentiment regardless of the lab numbers.
The market has been forgiving. Shares have climbed 19.5% since the last report, beating the S&P 500 by about 16 percentage points, and trade at $20.70, above the 200-day moving average of $19.52. That still leaves them roughly 9% below the post-earnings high of $22.78. Sentiment remains bearish but has improved from the prior quarter. Together, these suggest investors are giving management the benefit of the doubt on the fix. That patience raises the stakes. If collections show tangible recovery and the reduced guidance holds, the cut can be framed as a one-time stumble. If the billing problem lingers into the fourth quarter, the rally will look premature.